Daniel A. Pollyea, MD, MS

Learning more about monocytic resistance to venetoclax is a new direction toward improving outcomes for patients with acute myeloid leukemia.

Daniel Pollyea, MD, MS, discusses the unmet needs and future management strategies of acute myeloid leukemia.

An expert describes the considerations in choosing to treat acute myeloid leukemia patients with venetoclax.

Dr. Pollyea breaks down data from the recent VIALE-A phase III clinical trial.

A hematologist details the frontline treatment options and goals in acute myeloid leukemia and describes venetoclax.

Daniel Pollyea, MD, MS, explains the risk factors for acute myeloid leukemia, the importance of biomarker testing, and the challenges that prevent every patient from being tested.

Daniel A. Pollyea, MD, MS, discusses how far the field of acute myeloid leukemia has come in the last 1 to 2 years.

Daniel A. Pollyea, MD, MS, associate professor of medicine and clinical director of Leukemia Services at the University of Colorado School of Medicine, discusses some of the recent advancements in acute myeloid leukemia. Pollyea says researchers have been able to create more personalized treatments for many patients by doing targeted sequencing of patient samples.